NEW YORK (
was upgraded at Bank of America/Merrill Lynch to neutral from underperform. $99 price target. Company continues to buy back stock, BofA/Merrill said.
was downgraded at BMO Capital to market perform from outperform. Valuation call, based on an $11 price target, BMO Capital said.
was upgraded to buy at TheStreet Ratings.
was downgraded at Ardour Capital to reduce from hold. Valuation call, based on a $44 price target, Ardour Capital said.
was upgraded at Jefferies to buy from hold. $32 price target. Risk/reward is improving and video ads are coming in July, Jefferies said.
Facebook was upgraded at BMO Capital to outperform from market perform. $33 price target. Estimates were also boosted, given an expected upgraded video ad offering, BMO Capital said.
was upgraded at Goldman Sachs to buy from neutral. $64 price target. Earnings visibility is improving, Goldman Sachs said.
was upgraded at Wedbush to neutral from underperform. $12 price target. Linzess prescriptions are growing, Wedbush said.
was upgraded at Goldman Sachs to buy. The stock was also placed on the Conviction List, given improving industry fundamentals, Goldman said. $127 price target.
was upgraded at Goldman Sachs to buy. Expect upside to consensus expectations, Goldman said. $95 price target.
was downgraded at Nomura to neutral. Valuation call, based on a $21 price target, Nomura said.
was downgraded at Drexel Hamilton to hold from buy. Valuation call, as the stock exceeded the $30 price target, Drexel Hamilton said.
was upgraded at Wedbush to outperform from neutral. $40 price target. Cyclical catalyst should drive margin expansion, Wedbush said.
was upgraded at Goldman Sachs to neutral. Cash metrics are solid, Goldman said. $70 price target.
Also see: Long-Term Care Insurance 101 >>
was upgraded at Goldman Sachs to neutral from sell. Valuation call, based on an $18 price target, Goldman said.
was initiated with a market perform rating at BMO Capital. $34 price target. Company is facing increased competition, BMO Capital said.
was downgraded at UBS to sell from neutral. The acquisition of New Mexico Gas limits earnings growth and adds execution and regulatory risk, UBS said. Price target is now $16.
was downgraded at Goldman Sachs to neutral from buy. Company lacks near-term catalysts, Goldman said. $86 price target.
was downgraded at Goldman Sachs to neutral from buy. $86 price target. Timing of a Cessna recovery remains uncertain, Goldman said.
was upgraded to buy at TheStreet Ratings.
was initiated with an overweight rating at BMO Capital. $55 price target. Company is gaining market share, BMO Capital said.
STOCK COMMENTS / EPS CHANGES
price target and estimates were raised at UBS. Reflect the Warner Chilcott acquisition, said UBS. EPS accretion will be 35% in 2014 and 45% in 2015. Price target is now $155.
estimates, price target were increased at Oppenheimer. Estimates were boosted through 2014. Coventry acquisition should add to earnings, Oppenheimer said. Buy rating and new $74 price target.
estimates were raised at UBS. Rebound in wireless is being driven by the smartphone ramp, said UBS.
price target was raised at Nomura. Shares of AXP are now seen reaching $89. See upside to consensus expectations, Nomura said. Buy rating.
numbers were increased at BofA/Merrill. Estimates were raised through 2015. Tecfidera should help drive near-term growth, BofA/Merrill said. Buy rating and new $298 price target.
estimates were reduced at UBS. Slow start to the second quarter, strategic investment costs and promotional headwinds, said UBS.
numbers were boosted at Morgan Stanley. Shares are now seen reaching $74. Estimates were also increased, as the company's story continues to improve, Morgan Stanley said. Overweight rating.
estimates were raised at Citigroup for 2014. The company continues to gain traction abroad, said Citigroup.
was cut from Conviction Buy List at Goldman Sachs. No longer expect earnings upside potential, Goldman said. $33 price target.
price target and estimates were raised at UBS. Stronger revenue growth and operating leverage, said UBS. Price target is $56.
was added to the Conviction Buy List at Goldman Sachs. Sum-of-the-parts valuation is attractive, Goldman said. $10 price target.
>To submit a news tip, email:
and become a fan on
This article was written by a staff member of TheStreet.